Light’s role in regulating circadian rhythms—our internal biological clocks—has been firmly established across numerous studies. These rhythms influence sleep-wake cycles, hormone secretion, cognitive function, and overall metabolic health. However, age-related changes often impair circadian regulation, leading to diminished sleep quality, mood disturbances, and increased susceptibility to chronic diseases. By modulating light exposure, especially at critical times of the day, the circadian system can be reset or fine-tuned, promoting better physiological and psychological outcomes. The LightSPAN trial ambitiously leverages this concept via a mobile health platform, integrating chronotherapeutic principles into daily behavioural changes.

Chronotherapy, traditionally associated with timing medication administration to circadian phases, is now being expanded into behavioral interventions that target environmental cues, such as light. The essence is to align external signals with the body’s internal timing mechanisms, optimizing physiological functions. The LightSPAN intervention uniquely employs sophisticated algorithms embedded within mobile applications to guide users on optimal light exposure schedules. The technology personalizes recommendations, adapting to individual lifestyles and environmental contexts, thereby facilitating adherence and maximizing therapeutic efficacy.

Singapore’s rapidly aging population underscores the criticality of such innovations. With increased life expectancy comes a rise in age-associated conditions, many of which are exacerbated by circadian misalignment. The LightSPAN trial’s focus on adults aged 60 and above not only targets a vulnerable demographic but also situates the research within an urban environment characterized by distinct light pollution challenges and lifestyle patterns. This context offers a rich testing ground for mobile-based, chronotherapeutic interventions, potentially setting a global precedent.

The trial’s rigorous design—as a randomized, double-blind study—ensures the highest standards of scientific validity and reliability. Participants will be randomly allocated to either the LightSPAN intervention or a control group, with neither the subjects nor the researchers aware of the group assignments during the study. This methodology mitigates biases and strengthens the causal inferences between the chronotherapeutic intervention and health outcomes. Outcomes are anticipated to encompass multifaceted health indicators, including sleep quality, cognitive performance, mood, and cardiovascular parameters.

Technologically, the LightSPAN mHealth application integrates wearable sensors capable of monitoring real-time light exposure and physiological responses, such as heart rate variability and activity patterns. These data streams enable dynamic adjustments to the intervention protocols, fostering a highly responsive and individualized treatment pathway. By capitalizing on mobile technology, the study circumvents traditional barriers to intervention implementation, such as accessibility and compliance, particularly pertinent for older adults who may face mobility or transportation challenges.

One of the distinguishing features of LightSPAN is its chronotherapeutic timing strategy, which is rooted in circadian biology research. Light exposure timing is critical: morning bright light can advance circadian phases, promoting earlier sleep onset and improved alertness during the day, while evening light has the opposite effect. The intervention carefully calibrates these exposures to optimize circadian phase alignment, potentially mitigating issues like insomnia or excessive daytime sleepiness—common complaints in older populations that degrade quality of life.

Beyond sleep and circadian regulation, the trial explores broader systemic effects of optimized light exposure. Emerging evidence suggests that circadian alignment influences immune function, glucose metabolism, and even gene expression patterns linked to aging and longevity. By fine-tuning light-driven circadian cues, LightSPAN may elicit cascading benefits that extend to robust immune responses, better glycaemic control, and delayed onset of age-related diseases such as dementia or cardiovascular events.

The research team, comprising experts in geriatrics, chronobiology, digital health, and behavioural science, embodies a multidisciplinary approach essential for such complex investigations. Their integrated expertise allows for comprehensive assessment of the intervention’s efficacy, adherence, and psychological acceptability. Moreover, the inclusion of behavioural change techniques within the mHealth platform addresses motivational barriers in older adults, which are often overlooked but critical for sustainable health improvements.

Another technical innovation lies in the trial’s data analytics framework. Machine learning algorithms will analyze longitudinal data to identify individual response patterns and predictors of success or failure. This personalized data-driven analytic approach transcends traditional ‘one-size-fits-all’ health interventions and aligns with contemporary precision medicine trends. It also facilitates ongoing optimization of the LightSPAN algorithm throughout and beyond the trial duration.

The potential public health implications of LightSPAN are profound. Should the intervention prove efficacious, it can be scaled rapidly given its foundation in mobile technology, making it accessible not only in Singapore but also in other urban centers globally facing similar demographic changes. The cost-effectiveness of such non-pharmacological interventions further enhances their appeal amid escalating healthcare costs associated with aging populations.

There are, however, challenges inherent in implementing such a trial. Ensuring high compliance rates among older participants in a technology-driven intervention demands careful usability design and sustained engagement strategies. Environmental variability, such as differing indoor lighting conditions and outdoor exposure opportunities, may introduce complexities in standardizing intervention delivery. The researchers have anticipated these issues, incorporating adaptive and context-sensitive features within the mHealth platform to accommodate individual and environmental differences.

The LightSPAN trial is also notable for its ethical rigor, safeguarding participant privacy and data security within the digital health framework. Older adults represent a potentially vulnerable population, necessitating thorough informed consent processes and transparent communication about data usage. The research design emphasizes these ethical imperatives, aligning with global standards for digital health research involving human subjects.

As the trial progresses, its findings are poised to enrich the growing body of knowledge on the intersection of circadian science, aging biology, and digital therapeutics. Beyond validating the specific LightSPAN intervention, insights gained may stimulate further innovations in chronotherapeutic strategies applicable to other populations and conditions, such as shift workers, patients with mood disorders, or chronic illnesses affected by circadian dysregulation.

In summary, LightSPAN represents a visionary fusion of cutting-edge chronobiology, mobile health technology, and behavioral science, tailored to the complex needs of the aging population. By optimizing light exposure—a fundamental environmental cue—this intervention seeks to harmonize circadian rhythms, thereby enhancing sleep, cognitive function, and overall health in older adults. Its success could pave the way for a new era of personalized, time-based wellness interventions, making the management of age-related health challenges more accessible, effective, and engaging.

Subject of Research:

Article Title:

Article References:
Murukesu, R., Alkaff, Z.A., Del Villar, D. et al. Protocol for a randomised, double-blind trial of a chronotherapeutic mobile health (mHealth) behaviour change intervention to optimise light exposure among older adults aged ≥ 60 years in Singapore (LightSPAN). BMC Geriatr (2026). https://doi.org/10.1186/s12877-026-07105-6

Image Credits: AI Generated

DOI: 10.1186/s12877-026-07105-6

Keywords: chronotherapy, mobile health, mHealth intervention, light exposure, circadian rhythms, older adults, aging, behavioural change, sleep optimization, digital health, randomized controlled trial

The circadian clock within muscle cells intricately orchestrates the balance between protein synthesis and degradation, which is vital for sustaining muscle integrity. These cellular clocks align physiological functions with the day-night cycle, enhancing muscle repair and function during periods of rest. By employing zebrafish as a model organism, the researchers were able to visualize and manipulate muscle clock activity with high precision, taking advantage of the fish’s genetic similarity to humans and their transparent musculature, which facilitates direct microscopic observation.

Central to the findings is the concept of "nocturnal clearance," whereby muscle cells activate pathways at night to identify and dismantle defective or damaged proteins accumulated from daily activity. This proteolytic process is crucial to prevent the buildup of dysfunctional proteins that can impair muscle contraction and growth. The study shows that when the muscle clock’s function is compromised, this essential clearance mechanism falters, leading to a premature decline in muscle health characterized by symptoms remarkably similar to those observed in aged individuals and shift workers.

The researchers induced circadian disruption in zebrafish by overexpressing a mutant clock protein that impaired the normal rhythmic function in skeletal muscle cells. Over a two-year observation period, fish with dysfunctional muscle clocks displayed signs of accelerated ageing: decreased body length, reduced weight, diminished swimming speed, and lower activity levels. Such phenotypic changes closely resemble muscle decline in older humans, underscoring a conserved biological mechanism linking circadian dysregulation and sarcopenia.

At a molecular level, the study highlights that the muscle circadian clock governs proteostasis by regulating protein turnover through autophagy and the ubiquitin-proteasome system. During the active phase, muscle proteins endure stress and damage from continuous contraction and metabolic demands. The subsequent nocturnal phase activates catabolic pathways to clear these worn-out proteins, allowing for the synthesis of new, functional proteins. This cyclical renewal process is fundamental for muscle adaptation and longevity.

The implications of these findings extend beyond fundamental biology, addressing a pressing public health concern: shift work. Approximately four million individuals in the UK alone engage in nighttime or rotating shift schedules, often facing circadian misalignment. This research provides compelling mechanistic insight into how such lifestyle factors contribute to muscle degeneration and overall health decline. Muscular sarcopenia in shift workers could be a direct consequence of impaired circadian regulation of muscle cellular homeostasis.

Lead author Jeffrey Kelu explains that modulating the muscle clock pharmacologically may offer therapeutic avenues. Preclinical trials exploring clock-targeted drugs aim to restore nocturnal proteolytic activity and muscle function in circadian-disrupted models. This innovative approach could mitigate the deleterious effects of shift work and ageing on muscle health, improving quality of life for millions worldwide.

In addition to therapeutic potential, this work validates the zebrafish model as an invaluable tool for dissecting complex biological rhythms in muscle biology. Zebrafish genetics and transparent larvae enable live imaging of fluorescently labelled muscle membranes, providing quantitative data on muscle size and integrity. Professor Simon Hughes emphasizes that insights gained from this "simple" system can guide human studies, representing a critical translational bridge in chronobiology research.

The study also stresses the importance of synchronizing various tissue-specific clocks to overall circadian health. While systemic circadian rhythms governed by the central brain clock are well known, peripheral clocks in tissues such as muscle act autonomously to maintain local homeostasis. Disruption of these peripheral clocks, even when the central clock remains intact, can trigger tissue-specific ageing and dysfunction, as demonstrated in muscle.

Furthermore, the research touches upon the broader implications of circadian biology in proteostasis. Impaired clearance of damaged proteins is a hallmark not only of muscle ageing but also of neurodegenerative diseases and metabolic disorders. The muscle clock’s role in regulating proteolytic pathways may therefore have systemic repercussions, linking circadian dysregulation to a wide spectrum of age-related pathologies.

In conclusion, this seminal study provides a detailed mechanistic framework connecting muscle intrinsic clocks, protein turnover, and ageing. By elucidating how circadian disruption accelerates sarcopenia at cellular and organismal levels, it paves the way for targeted chronotherapeutic strategies. As modern societies increasingly depend on 24/7 labor schedules, understanding and mitigating the biological costs of circadian misalignment becomes ever more urgent for public health and longevity.

Subject of Research: Circadian disruption and muscle ageing (sarcopenia)

Article Title: Disruption of Muscle Intrinsic Circadian Clocks Accelerates Age-Related Sarcopenia through Impaired Proteostasis

News Publication Date: Not explicitly provided; article published recently

Web References: http://dx.doi.org/10.1073/pnas.2422446122

References: Study published in Proceedings of the National Academy of Sciences (PNAS), DOI 10.1073/pnas.2422446122

Image Credits: King’s College London

Keywords: Cell biology, circadian rhythms, muscle ageing, sarcopenia, protein turnover, zebrafish model, shift work, proteostasis